Pasar al contenido principal

NUEVAS ESTRATEGIAS EN LA PREVENCION, DIAGNOSTICO Y TRATAMIENTO DE LAS INFECCIONES ASOCIADAS CON LA ASISTENCIA SANITARIA

PID2021-122875OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION HOSPITAL UNIVERSITARIO LA FE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

SARS-COV-2 viral RNA detection through oligonucleotide-capped nanoporous anodic alumina supports.

  • López-Palacios, Alba|||0000-0002-4397-277X
  • Caballos-Gómez, María Isabel
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Aznar, Elena|||0000-0003-0361-3876
  • Aranda-Sobrino, María Nieves
  • Calbuig, Eva
  • Gómez-Ruiz, María Dolores
  • Tormo-Mas, M.A.
  • Peman, Javier
  • Climent Terol, Estela
[EN] We describe herein a sensor containing nanoporous anodic alumina (NAA) as sensing platform to identify SARSCOV-2 RNA using a gating mechanism. The system is based on NAA that contains a fluorescent dye (Rhodamine B; RhB) and is capped with an oligonucleotide sequence that hybridize specifically a region of SARS-CoV-2 genome. In the presence of RNA from SARS-COV-2 virus, the oligonucleotide of the surface is displaced, uncapping the pores, and producing a delivery of RhB. The detection of the virus is achieved measuring the fluorescence of the fluorophore. The nanosensor demonstrates to be highly sensitive and selective in aqueous buffers and in biological media, having a limit of detection (LOD) of 50 ± 30 copies mL-1 of SARS-CoV-2 RNA extracted from patients. Moreover, preliminary results using 18 real nasopharyngeal swab samples indicate the potential of the system to differentiate between infected and non-infected patients. Compared to the conventional RT-PCR method, in our system there is no need for sample pretreatment or RNA isolation, providing diagnostic outcomes within 60 mins while maintaining a high level of reliability, This study was sponsored by the Spanish Government (projects PID2021-126304OB-C41 (DOROTHY), PID2021-128141OB-C22 (ANTIVIBEM), and PID2021-122875OB-100 (MCUI/AEI/ FEDER, UE)), the Generalitat Valenciana (project no.2 RD 180/2020, CIPROM/ 2021/007), Supera COVID-19 Fund (DIACOVID project), the Universitat Polit`ecnica de Val`encia− Instituto de Investigacion ¿ Sanitaria La Fe (IISLaFe) (SARS-COV-2-SEEKER and VISION-COV projects). This research project has received funding from the European Union s HORIZON-CL4- 2022 research and innovation programme under grant agreement ID 101093042, PHOTONGATE project. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor th e granting authority can be held responsible for them. This work was supported by the European Research Council (ERC) via Advanced Grant (101052997, EDISON). Also, the project has received funding from the European Union s HORIZON-CL4-2022 research and innovation programme under grant agreement ID 101093042, PHOTONGATE project. A.L.P. thanks the Ministerio de Universidades for his predoctoral grant (FPU20/05297). E. C. thanks the Instituto de Salud Carlos III (Miguel Servet 2023 CP23/00086). Scheme 1 was done with BioRender.com. The Medicaments Research Ethics Committee, CEIm of University and Polytechnic La Fe Hospital of Valencia (2021-012-1) approved the use of samples from human patients.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 N protein IgG antibody detection employing nanoporous anodized alumina: A rapid and selective alternative for identifying naturally infected individuals in populations vaccinated with spike protein (S)-based vaccines

  • Esteve-Sánchez, Yoel|||0000-0002-6845-1110
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Aznar, Elena|||0000-0003-0361-3876
  • Tormo-Mas, M.A.
  • Peman, Javier
  • Eva Calbuig
  • Gomez, Maria Dolores
  • Climent Terol, Estela
[EN] Methods to detect naturally infected individuals, especially during or after a pandemic, are valuable in populations with a high rate of vaccination. Having in mind that after the COVID-19 pandemic people has been vaccinated against the virus by Spike protein (S)-based vaccines, we present in this paper a novel nanosensor based on gated nanoporous anodic alumina (NAA) material to detect naturally infected individuals in populations with high rates of vaccination. The nanosensor developed is based on a protein-capped nanomaterial for the identification of IgG antibodies that can detect nucleocapsid protein (N) of SARS-CoV-2. The NAA material has been loaded with an indicator (Rhodamine B (RhB)) and the pores of the material have been blocked with SARS-CoV-2 nucleocapsid protein (N) attached to a specific aptamer. In presence of antibodies against this antigen, the pores are uncapped, triggering the dye release and a fluorescent signal as a result. The biosensor has been tested in vitro and simulated serum for IgG detection, proving a detection limit of 1 mu g/mL. Moreover, specificity assays with N proteins from other coronaviruses have proved the robustness and efficacy of this nanosensor. Finally, the system has been tested on samples from patients that contained SARS-CoV-2 antibodies, demonstrating its potential for the discrimination of individuals that have been vaccinated or infected by SARS-CoV-2 virus., This research was supported by projects PID2021-126304OB-C41, PID2021-128141OB-C22, and PID2021-122875OB-100 funded by MCIN/AEI/10.13039/501100011033/and by European Regional Development Fund-A way of doing Europe. This work was also funded by the Generalitat Valenciana (project no.2 RD 180/2020, CIPROM/2021/007) , Santander and CRUE Supera COVID-19 Fund (DIACOVID project) , the Universitat Politecnica de Valencia-Instituto de Investigacion Sanitaria La Fe (IIS-LaFe) (SARS-COV-2-SEEKER and VISION-COV projects) . R.M thanks to the European Union's Horizon EUROPE Research and Innovation Program (grant agreement No 101093042) . Y.E.-S. acknowledges the Ministerio de Universidades for his predoctoral grant (FPU20/05297) . E.C. thanks the Instituto de Salud Carlos III (Miguel Servet 2023 CP23/00086) . Scheme 1 done with BioRender.com . The use of clinical samples from patients was approved by the Drug Research Ethics Committee, CEIm of Hospital Universitari i Politecnic La Fe of Valencia (2021-012-1) . In all cases was obtained an informed oral consent from all participants or next of kin prior to the research.r E.-S. acknowledges the Ministerio de Universidades for his predoctoral grant (FPU20/05297) . E.C. thanks the Instituto de Salud Carlos III (Miguel Servet 2023 CP23/00086) . Scheme 1 done with BioRender.com . The use of clinical samples from patients was approved by the Drug Research Ethics Committee, CEIm of Hospital Universitari i Polite`cnic ` cnic La Fe of Valencia (2021-012-1) . In all cases was obtained an informed oral consent from all participants or next of kin prior to the research.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Human Papilloma Virus DNA Detection in Clinical Samples Using Fluorogenic Probes Based on Oligonucleotide Gated Nanoporous Anodic Alumina Films

  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Caballos-Gómez, María Isabel
  • López-Palacios, Alba|||0000-0002-4397-277X
  • Aznar, Elena|||0000-0003-0361-3876
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Aranda, M. Nieves
  • Tormo-Mas, María Ángeles
  • Peman, Javier
  • Prieto Rodríguez, Mireya
  • Picornell, Carlos
[EN] In this work, fluorogenic probes based on oligonucleotide capped nanoporous anodic alumina films are developed for specific and sensitive detection of human papilloma virus (HPV) DNA. The probe consists of anodic alumina nanoporous films loaded with the fluorophore rhodamine B (RhB) and capped with oligonucleotides bearing specific base sequences complementary to genetic material of different high-risk (hr) HPV types. Synthesis protocol is optimized for scale up production of sensors with high reproducibility. The sensors' surfaces are characterized by scanning electron microscopy (HR-FESEM) and atomic force microscopy (AFM) and their atomic composition is determined by energy dispersive X-ray spectroscopy (EDXS). Oligonucleotide molecules onto nanoporous films block the pores and avoid diffusion of RhB to the liquid phase. Pore opening is produced when specific DNA of HPV is present in the medium, resulting in RhB delivery, that is detected by fluorescence measurements. The sensing assay is optimized for reliable fluorescence signal reading. Nine different sensors are synthesized for specific detection of 14 different hr-HPV types in clinical samples with very high sensitivity (100%) and high selectivity (93-100%), allowing rapid screening of virus infections with very high negative predictive values (100%)., The authors gratefully acknowledge financial support projects for PID2021-126304OB-C41 and PDI2021-122875OB-100 funded by MCIN/AEI /10.13039/501100011033 / FEDER, UE, project DTS18/00090 from Instituto de Salud Carlos III and FEDER and Generalitat Valenciana (Project PROMETEO CIPROM/2021/007). This work was also supported by CIBER -Consorcio Centro de Investigacion Biomedica en Red- (CB06/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion. The authors thank UPV electron microscopy service for technical support.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Aptamer-Capped Nanoporous Anodic Alumina for SARS-CoV-2 Spike Protein Detection

  • Caballos-Gómez, María Isabel
  • López-Palacios, Alba|||0000-0002-4397-277X
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Aznar, Elena|||0000-0003-0361-3876
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Aranda, María Nieves
  • Pla, Luis
  • Santiago Felipe, Sara
  • Tormo-Mas, María Ángeles
  • Pemán, Javier
  • Gómez-Ruiz, María Dolores
  • Calbuig, Eva
  • Sánchez-Sendra, Beatriz
  • Francés-Gómez, Clara
  • Geller, Ron
[EN] The COVID-19 pandemic, which began in 2019, has highlighted the importance of testing and tracking infected individuals as a means of mitigating the spread of the virus. In this context, the development of sensitive and rapid methods for the detection of SARS-CoV-2, the virus responsible for COVID-19, is crucial. Here, a biosensor based on oligonucleotide-gated nanomaterials for the specific detection of SARS-CoV-2 spike protein is presented. The sensing system consists of a nanoporous anodic alumina disk loaded with the fluorescent indicator rhodamine B and capped with a DNA aptamer that selectively binds the SARS-CoV-2 spike protein. The system is initially evaluated using pseudotype virus systems based on vesicular stomatitis virus carrying different SARS-CoV-2 S-proteins on their surface. When the pseudotype virus is present, the cap of the solid is selectively removed, triggering the release of the dye from the pore voids to the medium. The nanodevice demonstrated its ability to detect pseudotype virus concentrations as low as 7.5 center dot 10(3) PFU mL. In addition, the nanodevice is tested on nasopharyngeal samples from individuals suspected of having COVID-19., This study was supported by the Spanish Government (projects PID2021-126304OB-C41, and PID2021-122875OB-100 (MCUI/AEI/FEDER, UE)), the Generalitat Valenciana (project no.2 RD 180/2020, CIPROM/2021/007), Supera COVID-19 Fund (DIACOVID project), the Universitat Politecnica de Valencia-Instituto de Investigacion Sanitaria La Fe (IIS-LaFe) (SARS-COV-2-SEEKER and VISION-COV projects), and by the European Commission -NextGenerationEU, through CSIC's Global Health Platform (PTI Salud Global) to Ron Geller. The project leading to this application has received funding from the European Union's Horizon EUROPE research and innovation programme under grant agreement No 101093042. Isabel Caballos thanks the Instituto de Salud Carlos III for her predoctoral fellowship (IFI21/00008). Alba Lopez-Palacios thanks the Ministerio de Universidades for her predoctoral grant (FPU20/05297). Ron Geller holds a Ramon y Cajal fellowship from the Spanish Ministerio de Economia y Competitividad (RYC-2015-17517). Figure 1 done with BioRender.com. The use of samples from human subjects was approved by the Medicaments Research Ethics Commmittee, CEIm of Hospital Universitari i Politecnic La Fe (no. 2021-012-1). Informed written consent was obtained from all participants or next of kin prior to the research.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Test Strips Based on Gated Nanoporous Anodic Alumina for the Rapid and Accurate Detection of Pseudomonas aeruginosa in Clinical Samples

  • Torres-Mesado, Andrea
  • Patricia Bernabé-Quispe
  • Tormo-Mas, María Ángeles
  • Pemán, Javier
  • Climent Terol, Estela
  • Caballos-Gómez, María Isabel
  • López-Palacios, Alba|||0000-0002-4397-277X
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Aznar, Elena|||0000-0003-0361-3876
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Pseudomonas aeruginosa is a high-priority pathogen responsible for up to 23% of infections in intensive care units, yet current diagnostic methods remain hindered by multiday delays or high technical complexity. In this study, we report a rapid and highly sensitive biosensor based on nanoporous anodic alumina (NAA) capped with a specific oligonucleotide molecular gate targeting the phzA2 gene. The S3 biosensor achieved a limit of detection (LOD) of 0.153 ng mu L-1 for genomic DNA and an exceptional 28 CFU mL(-1) for direct bacterial detection without the need for prior DNA extraction. Validation in 63 clinical urine samples demonstrated a sensitivity of 91.67% and a specificity of 94.87% (AUC: 0.961, p-value < 0.0001). Furthermore, the sensor was integrated into Lateral Flow Assay (LFA), enabling the discrimination of positive and negative clinical samples in only 1 min with 100% specificity and 90.9% sensitivity. These results, combined with a one-year stability at 4 degrees C, position this gated-nanodevice as a robust and low-cost tool for Point-of-care (POC) diagnosis of P. aeruginosa infections., This research was funded by projects PID2024-155683OB-C41, PID2021-126304OB-C41, PID2021-122875OB-I00, and TED2021-132114B-100, supported by MCIN/AEI/10.13039/501100011033, the European Regional Development Fund, the European Union (NextGenerationEU/PRTR), and the Generalitat Valenciana (CIPROM/2021/007). This study is part of the Advanced Materials programme (MFA/2022/053) and was supported by MCIN with funding from the European Union's NextGenerationEU (PRTR-C17. I1) and by the Generalitat Valenciana. The project was also funded by Ayuntamiento de Valencia (SPI2024-096) and Instituto de Salud Carlos III (PI24/01239), cofunded by the European Union. In the same way, A.T. would like to thank the INVESTIGO program of the Ministry of Innovation, Universities, Research, and Digital Society of the Valencian Community for offering this research opportunity (INVEST/2023/443). To conclude, A.T. is grateful to the Asociacion Espanola Contra el Cancer for her 2024 predoctoral fellowship (PRDVA246577TORR (2024-0590-1)), which enabled this research. E.C. thanks the Instituto de Salud Carlos III (Miguel Servet 2023 CP23/00086), cofounded by the European Union. The authors thank Electron Microscopy Service at UPV for support. Funding for open access charge: CRUE-Universitat Politecnica de Valencia.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

In Situ-Forming Gels Loaded with Stimuli-Responsive Gated Mesoporous Silica Nanoparticles for Local Sustained Drug Delivery

  • De La Torre, Cristina
  • Coll, Carmen
  • Ultimo, Amelia
  • Ruiz-Hernández, Eduardo
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] A novel combination of in situ-forming hydrogels of hyaluronic acid with gated mesoporous materials was developed to design depots for local sustained release of chemotherapeutics. The depot consists of a hyaluronic-based gel loaded with redox-responsive mesoporous silica nanoparticles loaded with safranin O or doxorubicin and capped with polyethylene glycol chains containing a disulfide bond. The nanoparticles are able to deliver the payload in the presence of the reducing agent, glutathione (GSH), that promotes the cleavage of the disulfide bonds and the consequent pore opening and cargo delivery. Release studies and cellular assays demonstrated that the depot can successfully liberate the nanoparticles to the media and, subsequently, that the nanoparticles are internalized into the cells where the high concentration of GSH induces cargo delivery. When the nanoparticles were loaded with doxorubicin, a significant reduction in cell viability was observed. Our research opens the way to the development of new depots that enhance the local controlled release of chemotherapeutics by combining the tunable properties of hyaluronic gels with a wide range of gated materials., This research was funded by the Wellcome Trust Institutional Strategic Support Fund, the European Research Council under Grant Agreement No. 758887, and the European Union's Horizon 2020 research and Innovation program under Grant Agreement No. 952259 (NANOFACTS). We also thank the Spanish Government (projects PID2021-126304OB-C41 and PDI2021-122875OB-100) and the Generalitat Valenciana (project PROMETEO CIPROM/2021/007) for support.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

In Vivo Study of Osseointegrable Bone Calcium Phosphate (CaP) Implants Coated with a Vanillin Derivative

  • Medaglia, Serena|||0000-0003-3537-9842
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
  • Aznar, Elena|||0000-0003-0361-3876
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Bernabe-Quispe, Patricia
  • Tomás-Chenoll, Julia
  • Cebriá-Mendoza, María Concepción
  • Tormo-Mas, Maria Angeles
  • Primo Capella, Victor
  • Peris-Serra, José-Luis
[EN] Background/Objectives: Orthopaedic infections associated with implant surgery remain a major public health concern, often caused by bacterial colonization of implant surfaces. Staphylococcus epidermidis is among the most common pathogens involved. Developing antimicrobial bone implants that prevent infection without compromising bone regeneration is therefore essential. This study investigates the antimicrobial and osteointegrative performance of calcium phosphate (CaP) materials functionalized with vanillin, an essential oil component with known antimicrobial properties. Methods: Commercial CaP regenerative materials were covalently coated with vanillin. Antibacterial activity was evaluated against Staphylococcus epidermidis RP62A using viability assays. In vivo osseointegration was assessed in New Zealand female rabbits implanted with vanillin-coated and uncoated CaP scaffolds. Results: Vanillin-functionalized CaP scaffolds exhibited strong bactericidal activity at 24 h and bacteriostatic effects at 48 h at a concentration of 10 mg/mL. In vivo analyses showed no significant differences in osseointegration between vanillin-coated implants and control CaP materials. Conclusions: Vanillin-functionalized CaP materials maintain a high safety profile without impairing bone integration, supporting their potential use in clinical applications., This research was supported by projects PID2021-126304OB-C41, PID2021-128141OB-C22, PID2021-122875OB-100, PID2024-155683OB-C41 and PID2024-162542OB-I00 funded by MCIN/AEI/10.13039/501100011033/ and by European Regional Development Fund-a way of funding Europe. Also, this study forms part of the Advanced Materials programme (MFA/2022/053) and was supported by MCIN with funding from European Union NextGenerationEU (PRTR-C17.I1) and by Generalitat Valenciana. The study was also supported by Generalitat Valenciana (CIPROM/2021/007). This research was supported by CIBER -Consorcio Centro de Investigacion Biomedica en Red- (CB06/01/2012) and MICRO-STOP project, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion. All figures done with BioRender.com. S.M. thanks the Generalitat Valenciana for her Grisolia fellowship (GRISOLIAP/2018/149). M.C-M thanks the Generalitat Valenciana for the postdoctoral contract (INVEST/2022/381). Part of the equipment used to develop this work was supported by Generalitat Valenciana (IDIFEDER/2021/044) and is susceptible to be co-founded through the Operational Programme of the European Regional Development Fund. The authors also thank the Electron Microscopy Service at UPV for support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Aptamer-capped nanoporous anodic alumina for SARS-CoV-2 spike protein detection

  • Caballos, Isabel
  • Aranda, María Nieves
  • López-Palacios, Alba
  • Pla, Luis
  • Santiago-Felipe, Sara
  • Hernández-Montoto, Andy
  • Tormo-Mas, María Ángeles
  • Pemán, Javier
  • Gómez-Ruiz, María Dolores
  • Calabuig, Eva
  • Sánchez-Sendra, Beatriz
  • Francés-Gómez, Clara
  • Geller, Ron
  • Aznar, Elena
  • Martínez-Máñez, Ramón
The COVID-19 pandemic, which began in 2019, has highlighted the importance of testing and tracking infected individuals as a means of mitigating the spread of the virus. In this context, the development of sensitive and rapid methods for the detection of SARS-CoV-2, the virus responsible for COVID-19, is crucial. Herein, a biosensor based on oligonucleotide-gated nanomaterials for the specific detection of SARS-CoV-2 spike protein is presented. The sensing system consists of a nanoporous anodic alumina disk loaded with the fluorescent indicator rhodamine B and capped with a DNA aptamer that selectively binds the SARS-CoV-2 spike protein. The system is initially evaluated using pseudotype virus systems based on vesicular stomatitis virus carrying different SARS-CoV-2 S-proteins on their surface. When the pseudotype virus is present, the cap of the solid is selectively removed, triggering the release of the dye from the pore voids to the medium. The nanodevice demonstrated its ability to detect pseudotype virus concentrations as low as 7.5·103 PFU mL. In addition, the nanodevice is tested on nasopharyngeal samples from individuals suspected of having COVID-19., This study was supported by the Spanish Government (projects PID2021-126304OB-C41, and PID2021-122875OB-100 (MCUI/AEI/FEDER, UE)), the Generalitat Valenciana (project no.2 RD 180/2020, CIPROM/2021/007), Supera COVID-19 Fund (DIACOVID project), the Universitat Politècnica de València−Instituto de Investigación Sanitaria La Fe (IIS-LaFe) (SARS-COV-2-SEEKER and VISION-COV projects), and by the European Commission –NextGenerationEU, through CSIC's Global Health Platform (PTI Salud Global) to Ron Geller. The project leading to this application has received funding from the European Union's Horizon EUROPE research and innovation programme under grant agreement No 101093042. Isabel Caballos thanks the Instituto de Salud Carlos III for her predoctoral fellowship (IFI21/00008). Alba López-Palacios thanks the Ministerio de Universidades for her predoctoral grant (FPU20/05297). Ron Geller holds a Ramon y Cajal fellowship from the Spanish Ministerio de Economía y Competitividad (RYC-2015-17517)., Peer reviewed